Gross cystic disease (GCD) of the breast is a common benign breast disorder that can affect up to 7% of women in the West. Several studies have linked GCD to a subsequent increased risk of developing breast cancer (Haagensen, 1971; Bodian, 1990; Ciatto et al., 1990; Bundred et al., 1991; Naldoni et al., 1992; Bodian, 1993; Leis, 1993; Caraci et al., 1994) . In these studies gross cysts were defined as palpable cysts, larger than 1 cm, from which fluid could be aspirated. There has been some controversy in this field as a link between cystic disease and subsequent increased cancer risk was not detected in two large retrospective histological studies (Page et al., 1978; Dupont and Page, 1985) . However these histological studies did not separate the cysts into type 1 and type 2 and, more importantly, used a very inclusive definition of a cyst as being larger than 3 mm, thus including many cysts from which it would not be possible to obtain BCF. It seems likely that the outcome of studies on BCF differ from histological studies because they are examining different populations of cysts and it may be that only large aspiratable cysts are linked to an increased risk of subsequently developing breast cancer (Bundred et al., 1991) . However, some increased breast cancer risk has recently been reported (Dupont et al., 1993) linked to breast cysts, even using the 3-mm-diameter definition of a cyst.
Breast cysts can be classified according to their epithelial lining and the composition of the breast cyst fluid (BCF) that is aspirated from them. Type 1 cysts are lined with apocrine epithelium and contain BCF with a high level of potassium ions and a low level of sodium ions whereas type 2 cysts have a flattened epithelial lining and contain BCF with low potassium and high sodium ion concentrations. The increased risk of breast cancer is associated with type 1 cysts (Dixon et al., 1985; Bodian, 1993; Leis, 1993; Angeli et al., 1994) .
This association between cysts and cancer risk has led to a large number of studies on the composition of BCF. As tumours do not develop in the cyst lining at a greater frequency than in other breast tissue (Bodian, 1993) Breast cyst fluid contains a variety of hormones and growth factors, which it has been suggested may be implicated in the increased risk of developing breast cancer, including peptide growth factors such as gastrin-releasing peptide (Weber et al., 1989; Lai et al., 1990a) , epidermal growth factor (Hamed et al., 1990; Lai et al. 1990b ) and transforming growth factor (TGF)-j (Ness et al., 1993) . It has also been reported that the opiate peptide beta endorphin is present in BCF (Schurz et al., 1991; Schon et al., 1993) . This led us to attempt to measure another opiate peptide (Met-enkephalin-Arg-Phe) in BCF and in the course of that study we observed that proteolytic activities that cleaved this peptide were present in BCF (Frame and Parish, 1992) . It has been suggested that peptidases might modulate cell growth, including the growth of carcinomas, through the inactivation of peptide growth factors (Kenny et al., 1989) . As the presence of these peptidases in BCF may well reflect peptidase levels within the breast they are of interest as a possible factor in regulating breast cancer. In this paper we describe the characterisation of the peptidase activities in BCF that cleave Met-enkephalin-Arg-Phe. The assay for angiotensin-converting enzyme was adapted from Friedland and Silverstein (1976) . Aliquots of 10 ,ul of sample were incubated in a total volume of 250 ,l of 0.5 M potassium phosphate, 1.5 M sodium chloride 0.5 mM zinc chloride, pH 8.3, with 5 mM final concentration of hippurylHis-Leu at 37°C for 1 h. The reaction was terminated with 1.45 ml of 0.28 M sodium hydroxide and the product then incubated with 100,l of 2% o-phthaldialdehyde for 15 min at room temperature and this reaction terminated with 200 pl of 3.0 M hydrochloric acid. Fluorescence was measured with excitation at 360 nm and emission at 500 nm. A standard curve of His-Leu (from 0 to 10 nmol/tube of His-Leu) was incubated under these conditions for each assay. Samples that contained activity exceeding the upper limits of the standard curve were diluted 1:10 or 1:100 and reassayed. All samples and standards were assayed in duplicate and BCF samples were also treated at 100°C for 5 min and assayed in duplicate. The interassay coefficient of variation was 3.8%, determined by including aliquots of the same BCF in assays over a period of 3 months. This also demonstrated that the activity was stable on storage despite freezing and thawing.
Peptides, substrates, rabbit lung ACE and inhibitors were obtained from Sigma. Bothrops jararaca peptide is available as ACE inhibitor peptide from Sigma and is a proline-rich peptide (Ondetti et al., 1971) .
Enzyme activity in the two groups was compared using the Mann-Whitney test and correlation coefficients were calculated using Spearman's rank correlation method. . These same two peaks and no others were observed to be generated by the five different BCFs that were examined. The BCFs that had the greatest degree of proteolysis also had the greatest apparent immunoreactivity in a met-enkephalin-Arg-Phe radioimmunoassay (Frame and Parish, 1992) . A series of radiolabelled and unlabelled peptides were chromatographed with this gradient and another gradient (0-10% buffer B in 10 min followed by 10-60% in 40 min, data not shown) and these products of incubation with BCF did not chromatograph in the elution position of Tyr, Tyr-Gly, [1251] Tyr-Gly-Gly-Phe or ['25I]ArgTyr-Gly-Gly-Phe-Met.
To determine which proteases were involved in this proteolysis a type 1 BCF was incubated with a variety of inhibitors. Whereas inhibitors of thiol, aspartyl and serine proteases were relatively ineffective, EDTA, an inhibitor of metalloproteases, produced a marked inhibition (Table 1) . Therefore inhibitors of known metalloproteases that might cleave this peptide were examined and it was found that ACE inhibitors (captopril and Bothrops jararaca peptide) inhibited the formation of the peak eluting in the position of [125I]metenkephalin (Table I and Figure 2a ) and inhibitors of enkephalinase (phosphoramidon and thiorphan) inhibited the formation of the [125I]Tyr-Gly-Gly peak (Table I and Figure 3a) . BCF in the presence of thiorphan produced the same peaks as are produced by commercially available ACE (Figure 3a and b), whereas incubation with inhibitors of both peptidases together prevented all proteolysis (Table I and Figure 2b ). The inhibition by EDTA was reversed most effectively by Zn2+ rather than other divalent cations (Table   I ).
Separation of incubation products on HPLC was very useful for the initial identification of these enzyme activities; however, it is too time-consuming to form a routine assay. Therefore an assay for angiotensin-converting enzyme (Friedland and Silverstein, 1976) was employed, in which BCF samples were incubated with hippuryl-His-Leu, generating His-Leu, which is then converted to a fluorescent product. The generation of this product was inhibited by captopril and EDTA and the action of EDTA was reversed by zinc ions (Table II) . A low but detectable background level of fluorescence was present in BCF even when the fluid was boiled to inactivate enzymes. This was determined for each sample and subtracted from the fluorescence measured in the assay to arrive at the level of fluorescence due to enzyme activity. ACE activity was observed in all BCFs and is plotted as a scattergram against Na/K ratio (Figure 4a ). The same data are plotted with the BCFs classified as type 1 or type 2 by Na/K ratio (Figure 4b ) and the ACE levels in type 2 BCF are significantly higher than in type 1 (mean of 30.8 nmol h-110 jll-' compared with 6.1, P<0.001). Measurements of both serum and breast cyst fluid ACE levels were obtained from some patients ( Figure 5 ) and were inversely correlated (rs = -0.65, P< 0.05).
Discussion
The initial observation that the apparent immunoreactive met-enkephalin-Arg-Phe detected in BCF did not dilute in parallel with the standard curve led us to examine possible explanations. When radiolabelled peptide incubated under the same conditions was chromatographed on reverse-phase HPLC it was found that the peptide was cleaved into smaller fragments (Frame and Parish, 1992 Table I ). from the unlabelled peptides. Met-enkephalin-Arg-Phe has the sequence Tyr-Gly-Gly-Phe-Met-Arg-Phe and is only iodinated on the N-terminal tyrosine residue. As this method will only detect the radiolabelled products of peptide cleavage the only possible identities for the products are the iodinated forms of Tyr, Tyr-Gly, Tyr-Gly-Gly, Tyr-Gly-Gly-Phe, TyrGly-Gly-Phe-Met or Tyr-Gly-Gly-Phe-Met-Arg (as the last peptide is not commercially available we substituted Arg-TyrGly-Gly-Phe-Met, which we would expect to have an identical elution position in these systems). The product peaks detected corresponded to Tyr-Gly-Gly and to metenkephalin and not to any of the other possible peptide products. In order to characterise the activities a variety of protease inhibitors were added to the incubate and EDTA was found to be the most effective. As this is a metalloprotease inhibitor a variety of more specific inhibitors were investigated and of these enkephalinase and ACE inhibitors were found to be the most effective. ACE activity was also found in the serum of patients with BCF ( Figure 5 ), at similar levels to those measured in normal subjects with a hippuryl-His-Leu fluorimetric assay (Hayakari et al., 1984) . If ACE activity in breast cyst fluid were derived from the circulation (e.g. by a filtration process) then serum and BCF levels would correspond. However serum levels of ACE activity and the ACE levels in BCF showed an inverse correlation, which suggests that ACE in BCF is not derived by uptake from the circulation and probably originates from a local source. (Shipp et al., 1991) and as GRP and bombesin are potent growth-promoting factors for a wide variety of cancers (reviewed in Schrey and Patel, 1994) it seems possible that a reduction of enkephalinase expression by cancer cells is necessary for GRP to have a mitogenic effect. Indeed the growth of bombesin-dependent small-cell lung carcinomas is stimulated by enkephalinase inhibitors and reduced by exogenous enkephalinase (Shipp et al., 1991) . GRP is present in BCF (Weber et al., 1989) and is present in higher levels in type 1 fluids, leading to the suggestion that it is a factor in the increased risk associated with type 1 BCF (Lai et al. 1990a) . If enkephalinase action in BCF. and in the breast environment in general, is protective against the mitogenic actions of GRP then it might be expected that enkephalinase levels would be lower in type 1 BCF which is associated with an increased risk of cancer, and higher in type 2 fluids where there is no such association. This possibility is currently being investigated. Although this discussion has concentrated on GRP because of its potent growth-promoting effects. it is known that enkephalinase can cleave several other peptides (Kenny,. 1993) . including mitogenic peptides found in BCF. For example enkephalinase can cleave calcitomnn gene-related peptide (CGRP) (Katayama et al.. 1991) . which is present in BCF and can be mitogenic (Weber et al.. 1989) . as well as opiate peptides. such as met-enkephalin-Arg Phe. whose levels in BCF have not yet been determined. Similar arguments can be put forward for the involvement of ACE in the link between GCD and breast cancer. Serum ACE levels are decreased in patients with lung, breast and gastrointestinal tumours (Schweisfurth et al.. 1985: Varela and Saez, 1993) . which may represent a decrease in a protective effect. ACE is capable of cleaving many peptides (Hooper. 1991) (Shipp et al., 1991; Ganju et al., 1994) . and determining the effect of these inhibitors on tumour growth in in vivo models.
